Spero Therapeutics, Inc. (SPRO)
1.225
+0.02
(+2.08%)
USD |
NASDAQ |
Sep 02, 16:00
1.225
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Cash from Investing (Quarterly) : 0.00 for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | -0.129M |
| June 30, 2022 | 50.00M |
| March 31, 2022 | -16.06M |
| Date | Value |
|---|---|
| December 31, 2021 | -23.28M |
| September 30, 2021 | 17.02M |
| June 30, 2021 | 10.92M |
| March 31, 2021 | 3.003M |
| December 31, 2020 | -39.74M |
| September 30, 2020 | 3.949M |
| June 30, 2020 | 18.48M |
| March 31, 2020 | 27.78M |
| December 31, 2019 | -4.099M |
| September 30, 2019 | -15.89M |
| June 30, 2019 | 24.84M |
| March 31, 2019 | 24.67M |
| December 31, 2018 | 7.287M |
| September 30, 2018 | -72.62M |
| June 30, 2018 | 5.00M |
| March 31, 2018 | -22.82M |
| December 31, 2017 | -0.027M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 6.147M |
| Fortress Biotech, Inc. | -0.079M |
| Kura Oncology, Inc. | 92.21M |
| Legend Biotech Corp. | -120.10M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.355M |
| Free Cash Flow | 19.58M |
| Free Cash Flow Per Share (Quarterly) | -0.0924 |
| Free Cash Flow to Equity (Quarterly) | -4.924M |
| Free Cash Flow to Firm (Quarterly) | -5.355M |
| Free Cash Flow Yield | 27.69% |